Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1012-1017

  Wang, Jennifer R ^a   Gramling, Sarah J B ^b   Goldstein, David P ^a   Cheng, Dangxiao ^a   Chen, Duoduo ^a   Azad, Abul K ^a   Tse, Alvina ^a   Hon, Henrique ^a   Chen, Zhuo ^a   Mirshams, Maryam ^a   Simpson, Colleen ^a   Huang, Shao Hui ^a   Marquez, Stephanie ^b   O'Sullivan, Brian ^a   Liu, Fei Fei ^a   Roberts, Heidi ^a   Xu, Wei ^a   Brown, Dale H ^a   Gilbert, Ralph W ^a   Gullane, Patrick J ^a   Irish, Jonathan C ^a   Reisman, David N ^b   Liu, Geoffrey ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRM PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HOMOZYGOTE; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS;

EID: 84877113050     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt008     Document Type: Article

References (28)

1. Parkin, D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Argiris, A. et al. (2008) Head and neck cancer. Lancet, 371, 1695-1709.
3. Scully, C. et al. (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol., 36, 311-327.
4. Gollin, S.M. (2001) Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck, 23, 238-253.
5. van der Riet, P. et al. (1994) Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res., 54, 1156-1158.
6. Gunduz, E. et al. (2009) Loss of heterozygosity at the 9p21-24 region and identification of BRM as a candidate tumor suppressor gene in head and neck squamous cell carcinoma. Cancer Invest., 27, 661-668.
7. Reisman, D.N. et al. (2003) Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res., 63, 560-566.
8. Fukuoka, J. et al. (2004) Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin. Cancer Res., 10, 4314-4324.
9. Reisman, D. et al. (2009) The SWI/SNF complex and cancer. Oncogene, 28, 1653-1668.
10. Glaros, S. et al. (2007) The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene, 26, 7058-7066.
11. Gramling, S. et al. (2011) Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene, 30, 3289-3294.
12. Shen, H. et al. (2008) The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res., 68, 10154-10162.
13. Yamamichi, N. et al. (2007) Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res., 67, 10727-10735.
14. Liu, G. et al. (2011) Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene, 30, 3295-3304.
15. Menezes, R.J. et al. (2010) Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer, 67, 177-183.
16. Wong, K. et al. (2010) Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother. Oncol., 95, 339-343.
17. Yamamichi, N. et al. (2005) The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene, 24, 5471-5481.
18. Bock, V.L. et al. (2011) BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. Br. J. Dermatol., 164, 1221-1227.
19. Strober, B.E. et al. (1996) Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol. Cell. Biol., 16, 1576-1583.
20. Gleich, L.L. et al. (2002) Molecular genetics of head and neck cancer. Cancer Control, 9, 369-378.
21. Bartlett, C. et al. (2011) BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest. J. Cell. Physiol., 226, 1989-1997.
22. Reyes, J.C. et al. (1998) Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J., 17, 6979-6991.
23. Munger, K. et al. (2002) Human papillomavirus immortalization and transformation functions. Virus Res., 89, 213-228.
24. Chaturvedi, A.K. et al. (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol., 29, 4294-4301.
25. Gillison, M.L. et al. (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst., 100, 407-420.
26. Fickett, J.W. (1996) Quantitative discrimination of MEF2 sites. Mol. Cell. Biol., 16, 437-441.
27. Gregoire, S. et al. (2007) Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. Cell. Biol., 27, 1280-1295.
28. Johnstone, R.W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov., 1, 287-299.